Biocept

Biocept’s services are available to all disciplines of oncology clinicians and researchers. Biocept is dedicated to supporting its partners, collaborators, and clients with our unique CNSide™ CSF-TC and cfDNA technology platforms for rare event detection and genetic characterization. Biocept is fully approved, licensed and accredited by the states of California, Maryland, Pennsylvania, and Rhode Island; CLIA, and Medicare/Medicaid and CAP. Biocept is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. Biocept has developed a unique, patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). Our CNSide™ platform provides flexibility for developing assays with unique requirements for our pharma or biotechnology partners. We focus on providing high-level, personalized service to our clients, addressing critical questions of interest to them including:. Our experts have spent years working to change the way physicians look at cerebrospinal fluid (CSF) in cancer patients.